Skip to main content
OpenTrials
Completed

NCT Number: NCT04271969

Clinical Effectiveness Of High Frequency Chest Wall Oscillation (HFCWO) In A Bronchiectasis Population

The primary objective is to compare the patient's baseline QoL prior to HFCWO use against the patient's QoL at various study timepoints over a one-year period of HFCWO use.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bronchiectasis Bronchial Diseases Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Alabama - Birmingham (UAB University Hospital), Birmingham, Alabama, United States

Loading trial locations.

About this study

This study will use a prospective interventional comparative study design using the patient's quality of life (QoL) as the primary study endpoint to determine HFCWO affect. The study will compare the patient's QoL baseline (established at enrollment prior to HFCWO treatment) to the QoL measured at various timepoints (enrollment, 2 months, 6 months and 12 months) over a one-year period whilst receiving HFCWO treatment. In addition, a baseline for the secondary endpoints will established at enrollment for comparison to measurements taken at various timepoints over a one-year period whilst receiving HFCWO treatment. The patient's medical records will be used to establish prior histories of exacerbation rates for comparison to exacerbation rates experienced after one year of HFCWO treatment. Patients will serve as their own control.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older
  • Previous diagnosis of bronchiectasis confirmed by HRCT within the last 6 months
  • Patients must have at least 6 months of medical records related to bronchiectasis
  • Patients must be stable and currently on a standard of care regimen for bronchiectasis such as hypertonic saline and/or PEP
  • Patients with 1 or more exacerbations within the last 12 months
  • Previous and existing productive cough
  • No previous HFCWO use

Exclusion criteria

  • Patients who are known to have cystic fibrosis
  • Patients who are known to have primary ciliary dyskinesia (PCD)
  • Patients with chronic obstructive pulmonary disease (COPD) without bronchiectasis
  • Patients breathing via an artificial airway
  • Severe bronchospasm based on exam or history
  • Any comorbidity(ies) or contraindications that would normally complicate tolerating HFCWO treatment

Treatment and study plan

SmartVest Airway Clearance System

Device

Pulmonary airway clearance of retained mucus via high frequency chest wall oscillation (SmartVest)

Primary outcomes

  1. Quality of Life (QoL): Quality of Life-Bronchiectasis (QOL-B) questionnaire

    Time frame: 1 year

    The primary endpoint is the subject's quality of life (QoL) using the Quality of Life-Bronchiectasis (QOL-B) questionnaire as the measurement tool. QoL measured at enrollment (baseline) will be compared to QoL measured at 2 months, 6 months and 1 year.

    The previously validated questionnaire is titled "Quality of Life Questionnaire - Bronchiectasis". The Likert style questionnaire asks the subject to subjectively rank their symptoms using a 4 scale base ranging from "a lot of difficulty" to "no difficulty" and "always" to "never".

Secondary outcomes

  1. Clinical Measurements

    Time frame: 1 year

    • Exacerbation rates

    a. Pre HFCWO exacerbation rates will be established by review of the patient's medical records. Post HFCWO will recorded at 2 months, 6 months and 1 year.

    • Exacerbation frequency
    • The time to the subject's next exacerbation will be recorded for comparison pre to post HFCWO
    • Lung function (FEV1, FVC, FEF25-75) measured by standard spirometry
    • Sputum production measured by using the Breathlessness, Cough and Sputum Scale (BCSS) questionnaire
    • Patient adherence to HFCWO treatment measured by SmartVest Connect wireless feature
    • Six-minute walk test measured using American Thoracic Society standard test guidelines/protocol
    • Radiographic changes compare patient's original high-resolution computerized tomography (HRCT) taken to initially

Sponsors and collaborators

Lead sponsor

Electromed, Inc.

Industry

Collaborators

  • University of Alabama at Birmingham

Registry information

Acronym: HFCWO

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Feb 17, 2020
Registry last updated
Dec 7, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.